<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="10816" end="10820" sStart="10760" offset="56" sid="r7.1.use.v.0524" wn="1" wnkey="use%2:34:01::" annotator="cgozo" text="Both parametric and non-parametric tests were used because the distributional assumptions required for parametric testing may not be satisfied in all cases." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="13713" end="13720" sStart="null" offset="84" sid="r8.suggest.v.0343" wn="3" wnkey="suggest%2:32:02::" annotator="brubin" text="Although the sample numbers are too low to draw a firm conclusion, the data suggest a possible decrease in staining frequency by both antibodies in the transition from dysplasia to CIS ( p = 0.117 for Ki-67 and p = 0.080 for MCM2) (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="9906" end="9912" sStart="null" offset="102" sid="r11.strong.j.0170" wn="1" wnkey="strong%3:00:00::" annotator="anfahmy" text="The staining intensity was categorically coded as 0 (absent), 1 (weak), 2 (moderate), or 3 (strong)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="5569" end="5574" sStart="null" offset="6" sid="r7.serve.v.0154" wn="1" wnkey="serve%2:42:03::" annotator="jeneale" text="These serve as components of &quot;licensing factor,&quot; which is essential for initiation of DNA replication and for limiting replication to one round per cell cycle [ 26, 27]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-1-6.anc" start="65" end="69" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="cgozo" text="The 5-year survival &lt;b&gt;rate&lt;/b&gt; for patients with lung cancer is approximately 15%, and it has changed only marginally in the last 30 years [ 1]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-1-6.anc" start="65" end="69" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="brubin" text="The 5-year survival &lt;b&gt;rate&lt;/b&gt; for patients with lung cancer is approximately 15%, and it has changed only marginally in the last 30 years [ 1]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="5975" end="5981" sStart="null" offset="42" sid="r9.normal.j.0067" wn="1" wnkey="normal%3:00:01::" annotator="veweser" text="We previously demonstrated [ 25] that, in normal tissues, MCM2 is detectable only in proliferating cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="13559" end="13565" sStart="null" offset="32" sid="r9.normal.j.0651" wn="3" wnkey="normal%3:00:03::" annotator="cgozo" text="010) and increased from normal mucosa to metaplasia and from metaplasia to dysplasia." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="5975" end="5981" sStart="null" offset="42" sid="r9.normal.j.0067" wn="3" wnkey="normal%3:00:03::" annotator="cgozo" text="We previously demonstrated [ 25] that, in normal tissues, MCM2 is detectable only in proliferating cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="8440" end="8446" sStart="null" offset="314" sid="r9.normal.j.0912" wn="1" wnkey="normal%3:00:01::" annotator="brubin" text="In 41 specimens, the morphology was comparable between the original slide and slide 5. These 41 specimens were used for IHC analysis and included morphologically normal bronchial mucosa, metaplasia, dysplasia, and CIS (see Table 1for the numbers of specimens with normal and abnormal morphology)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="20886" end="20892" sStart="null" offset="93" sid="r9.normal.j.0340" wn="1" wnkey="normal%3:00:01::" annotator="brubin" text="Results obtained are easy to interpret, since there is a striking difference between normal bronchoepithelium and premalignant lesions." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="5975" end="5981" sStart="null" offset="42" sid="r9.normal.j.0067" wn="1" wnkey="normal%3:00:01::" annotator="brubin" text="We previously demonstrated [ 25] that, in normal tissues, MCM2 is detectable only in proliferating cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="5975" end="5981" sStart="null" offset="42" sid="r9.normal.j.0067" wn="2" wnkey="normal%3:00:02::" annotator="anfahmy" text="We previously demonstrated [ 25] that, in normal tissues, MCM2 is detectable only in proliferating cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="20814" end="20818" sStart="null" offset="21" sid="r7.1.easy.j.0159" wn="1" wnkey="easy%3:00:01::" annotator="brubin" text="Results obtained are easy to interpret, since there is a striking difference between normal bronchoepithelium and premalignant lesions." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-1-6.anc" start="665" end="671" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="veweser" text="Tumor stage is the most significant prognostic parameter for 5-year survival, but even patients with non-small cell lung cancer (non-SCLC) in pathologic stage IA disease (a tumor of less than 3 cm diameter located in one lobe of the lung and more than 2 cm from the carina without visceral pleural involvement, atelectasis, or pneumonitis, and absence of metastatic spread to regional lymph nodes) have a 33% &lt;b&gt;chance&lt;/b&gt; of recurrence within 5 years after complete surgical resection (lobectomy with mediastinal lymph node dissection) [ 2]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-1-6.anc" start="665" end="671" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="veweser" text="Tumor stage is the most significant prognostic parameter for 5-year survival, but even patients with non-small cell lung cancer (non-SCLC) in pathologic stage IA disease (a tumor of less than 3 cm diameter located in one lobe of the lung and more than 2 cm from the carina without visceral pleural involvement, atelectasis, or pneumonitis, and absence of metastatic spread to regional lymph nodes) have a 33% &lt;b&gt;chance&lt;/b&gt; of recurrence within 5 years after complete surgical resection (lobectomy with mediastinal lymph node dissection) [ 2]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-1-6.anc" start="665" end="671" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="rstandig" text="Tumor stage is the most significant prognostic parameter for 5-year survival, but even patients with non-small cell lung cancer (non-SCLC) in pathologic stage IA disease (a tumor of less than 3 cm diameter located in one lobe of the lung and more than 2 cm from the carina without visceral pleural involvement, atelectasis, or pneumonitis, and absence of metastatic spread to regional lymph nodes) have a 33% &lt;b&gt;chance&lt;/b&gt; of recurrence within 5 years after complete surgical resection (lobectomy with mediastinal lymph node dissection) [ 2]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-1-6.anc" start="665" end="671" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="elstickles" text="Tumor stage is the most significant prognostic parameter for 5-year survival, but even patients with non-small cell lung cancer (non-SCLC) in pathologic stage IA disease (a tumor of less than 3 cm diameter located in one lobe of the lung and more than 2 cm from the carina without visceral pleural involvement, atelectasis, or pneumonitis, and absence of metastatic spread to regional lymph nodes) have a 33% &lt;b&gt;chance&lt;/b&gt; of recurrence within 5 years after complete surgical resection (lobectomy with mediastinal lymph node dissection) [ 2]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-1-6.anc" start="665" end="671" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="comcgeetubb" text="Tumor stage is the most significant prognostic parameter for 5-year survival, but even patients with non-small cell lung cancer (non-SCLC) in pathologic stage IA disease (a tumor of less than 3 cm diameter located in one lobe of the lung and more than 2 cm from the carina without visceral pleural involvement, atelectasis, or pneumonitis, and absence of metastatic spread to regional lymph nodes) have a 33% &lt;b&gt;chance&lt;/b&gt; of recurrence within 5 years after complete surgical resection (lobectomy with mediastinal lymph node dissection) [ 2]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-1-6.anc" start="665" end="671" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="chisom" text="Tumor stage is the most significant prognostic parameter for 5-year survival, but even patients with non-small cell lung cancer (non-SCLC) in pathologic stage IA disease (a tumor of less than 3 cm diameter located in one lobe of the lung and more than 2 cm from the carina without visceral pleural involvement, atelectasis, or pneumonitis, and absence of metastatic spread to regional lymph nodes) have a 33% &lt;b&gt;chance&lt;/b&gt; of recurrence within 5 years after complete surgical resection (lobectomy with mediastinal lymph node dissection) [ 2]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-1-6.anc" start="665" end="671" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="carichter" text="Tumor stage is the most significant prognostic parameter for 5-year survival, but even patients with non-small cell lung cancer (non-SCLC) in pathologic stage IA disease (a tumor of less than 3 cm diameter located in one lobe of the lung and more than 2 cm from the carina without visceral pleural involvement, atelectasis, or pneumonitis, and absence of metastatic spread to regional lymph nodes) have a 33% &lt;b&gt;chance&lt;/b&gt; of recurrence within 5 years after complete surgical resection (lobectomy with mediastinal lymph node dissection) [ 2]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-1-6.anc" start="665" end="671" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="carichter" text="Tumor stage is the most significant prognostic parameter for 5-year survival, but even patients with non-small cell lung cancer (non-SCLC) in pathologic stage IA disease (a tumor of less than 3 cm diameter located in one lobe of the lung and more than 2 cm from the carina without visceral pleural involvement, atelectasis, or pneumonitis, and absence of metastatic spread to regional lymph nodes) have a 33% &lt;b&gt;chance&lt;/b&gt; of recurrence within 5 years after complete surgical resection (lobectomy with mediastinal lymph node dissection) [ 2]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="592" end="599" sStart="null" offset="392" sid="r11.absence.n.0702" wn="1" wnkey="absence%1:26:00::" annotator="adelpriore" text="Tumor stage is the most significant prognostic parameter for 5-year survival, but even patients with non-small cell lung cancer (non-SCLC) in pathologic stage IA disease (a tumor of less than 3 cm diameter located in one lobe of the lung and more than 2 cm from the carina without visceral pleural involvement, atelectasis, or pneumonitis, and absence of metastatic spread to regional lymph nodes) have a 33% chance of recurrence within 5 years after complete surgical resection (lobectomy with mediastinal lymph node dissection) [ 2]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-1-6.anc" start="17888" end="17892" sStart="null" offset="93" sid="r11.able.j.0285" wn="1" wnkey="able%3:00:00::" annotator="adelpriore" text="It can thus be concluded that cytological examination of sputum specimens is able to detect adenocarcinomas at an early stage albeit with low sensitivity (15%)." />
  </sentences>
</list>